^
Association details:
| Biomarker: | MGMT unmethylation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Intratumoural and intracavitary administration of ipilimumab plus nivolumab is feasible and safe in recurrent glioblastoma
Published date:
12/12/2020
Excerpt:
60 year old female patient with recurrent glioblastoma (IDH1 wild type, MGMT-promotor unmethylated) in cohort 3 (biopsy only) who previously progressed after concomitant radio-/chemotherapy and 4 cycles of chemotherapy with temozolomide achieved a complete response on study treatment that is still ongoing at 92 weeks.
Trial ID:
